Latest News

  • Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder Read More
  • Alkermes to Acquire Rodin Therapeutics Read More
  • Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences Read More

Investors

Working at Alkermes